Contact Us
Menu

B-hPD-1/hCD27 mice

Home Animal & Cell Models Humanized Immune-Checkpoint Mice B-hPD-1/hCD27 mice

Basic Information

Strain Name
C57BL/6-Pdcd1tm1(PDCD1) Cd27tm1(CD27)/Bcgen
Stock Number
120518
Common Name
B-hPD-1/hCD27 mice
Source/Investigator
Bcgen (Beijing Biocytogen Co., Ltd)
Related Genes
PD-1(Programmed death-1) ； CD27(CD27 molecule)
Appearance
Black
Genotypes
Homozygous
Gene description
PD-1 (Programmed death-1) is mainly expressed on the surface of T cells and primary B cells. The two PD-1 ligands, PD-L1 and PD-L2, are widely expressed on antigen-presenting cells (APCs). PD-1 interacts with its ligands and plays an important role in the negative regulation of the immune response. PD-L1 protein expression is detected in many human tumor tissues. PD-L1 expression in tumor cells could be induced by the microenvironment of tumor cells. PD-L1 expression is favorable for tumorigenesis and growth, for induction of anti-tumor T Cell Apoptosis, and for escaping responses by the immune system. Inhibition of PD-1 binding to its ligand can result in tumor cells that are exposed to the killing version of the immune system, and thus is a target for cancer treatments. CD27 is a TNF receptor super family member. It is expressed on the surface of T and B cells, and its binding with CD70 provides a co-stimulatory signal for T and B Cell Proliferation and for B cells producing immunoglobulins. Treating mice with a CD27 agonist antibody effectively enhanced the antitumor immune response for lymphoma and B16 melanoma, providing putative targets for tumor immunotherapy.

Description

PD-1 (Programmed death-1) is mainly expressed on the surface of T cells and primary B cells. The two PD-1 ligands, PD-L1 and PD-L2, are widely expressed on antigen-presenting cells (APCs). PD-1 interacts with its ligands and plays an important role in the negative regulation of the immune response. PD-L1 protein expression is detected in many human tumor tissues. PD-L1 expression in tumor cells could be induced by the microenvironment of tumor cells. PD-L1 expression is favorable for tumorigenesis and growth, for induction of anti-tumor T Cell Apoptosis, and for escaping responses by the immune system. Inhibition of PD-1 binding to its ligand can result in tumor cells that are exposed to the killing version of the immune system, and thus is a target for cancer treatments.

CD27 is a TNF receptor super family member. It is expressed on the surface of T and B cells, and its binding with CD70 provides a co-stimulatory signal for T and B Cell Proliferation and for B cells producing immunoglobulins. Treating mice with a CD27 agonist antibody effectively enhanced the antitumor immune response for lymphoma and B16 melanoma, providing putative targets for tumor immunotherapy.

Targeting Strategy

Gene targeting strategy for B-hPD-1/hCD27 mice . The exon 2 of mouse Pdcd1 gene that encode the extracellular domain were replaced by human PD-1 exon 2, The exons 1-5 of mouse Cd27 gene that encode the extracellular domain were replaced by human CD27 exons 1-5 in B-hPD-1/hCD27 mice.

Details

Phenotype

Protein Expression Analysis

Strain specific CD27 expression analysis in homozygous B-hPD-1/hCD27 mice by flow cytometry. Splenocytes were collected from WT and homozygous B-hPD-1/hCD27 mice stimulated with anti-CD3ε in vivo, and analyzed by flow cytometry with species-specific anti-CD27 antibody. Mouse CD27 was detectable in WT and B-hPD-1/hCD27 mice. Human CD27 were exclusively detectable in B-hPD-1/hCD27 mice but not WT mice. This might result from the cross-recognition of hCD27 by anti-mCD27 antibodies.

Strain specific PD-1 expression analysis in homozygous B-hPD-1/hCD27 mice by flow cytometry. Splenocytes were collected from WT and homozygous B-hPD-1/hCD27 mice stimulated with anti-CD3ε in vivo, and analyzed by flow cytometry with species-specific anti-PD-1 antibody. Mouse PD-1 was exclusively detectable in WT mice. Human PD-1 were exclusively detectable in B-hPD-1/hCD27 mice but not WT mice.

References

  1. J Immunol. 2013 Oct 15;191(8):4174-83. doi: 10.4049/jimmunol.1300409. Epub 2013 Sep 11.
  2. Blood. 2017 Jul 20;130(3):297-309. doi: 10.1182/blood-2016-12-756585. Epub 2017 May 11.
  3. J Clin Oncol. 2017 Jun 20;35(18):2028-2036. doi: 10.1200/JCO.2016.70.1508. Epub 2017 May 2.
  4. Immunotherapy. 2015;7(6):655-67. doi: 10.2217/imt.15.32. Epub 2015 Jun 22.
  5. Nat Commun. 2017 Feb 6; 8: 14369. doi: 10.1038/ncomms14369.
  6. EMBO J. 1992 Nov;11(11):3887-95.
  7. J Exp Med. 2000 Oct 2;192(7):1027-34.
  8. Science. 2001 Jan 12;291(5502):319-22.
Request a Quote
Request a Quote
Back to top